Casgevy and Lyfgenia: Two gene therapies approved for sickle cell disease
Yale doctors discuss the implications of these treatments recently approved by the FDA for those with the debilitating blood disorder.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Gene Therapy | Genetics | Health | Science | Sickle Cell Anemia | Universities & Medical Training | Yale